Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...

Fintel reports that on March 31, 2025, BTIG upgraded their outlook for Progyny (NasdaqGS:PGNY) from Neutral to Buy. Analyst ...

BTIG upgraded Progyny (PGNY) to Buy from Neutral with a $28 price target The firm says the company’s demand is coming back up, the stock’s ...

CrowdStrike (CRWD) was upgraded from Neutral to Buy by BTIG, and maintains a $431 price target on the stock. Market Domination hosts Julie Hyman and Josh Lipton break down BTIG's reasons for the ...

Investing.com -- BTIG downgraded Ally Financial (NYSE:ALLY) Inc to Sell from Neutral with a $30 target saying a challenging macroeconomic condition and increased competition in the auto lending ...

Shares of CrowdStrike ( CRWD 3.34%) surged higher on Monday. The company's stock had gained 3.7% as of 10:50 a.m. ET but had ...

On Monday, BTIG analysts maintained a Neutral rating on Venus Concept Inc. (NASDAQ:VERO) after the company reported lower-than-expected Q4 revenue. Venus Concept disclosed a quarterly revenue of $ ...

BTIG analysts highlighted a historical trend suggesting a potential rebound for the S&P 500 (SPX) in April following a ...

U.S. equities mostly gained at midday on continued optimism about tariffs and a solid increase in home prices.